Global Expansion Jubilant Biosys is actively expanding its footprint with new office spaces in India and Europe, presenting opportunities to offer CRDMO services that align with their growth phase and regional capabilities in Asia and Europe.

Strategic Partnerships The company has a history of high-profile collaborations, including a CNS-focused expansion with Sanofi. This signals openness to co-development and discovery partnerships that can be targeted for joint research, early-stage discovery, or alliance-based outsourcing.

Integrated Capabilities With end-to-end offerings from drug discovery to GMP manufacturing and a strong discovery services pipeline, there are cross-sell opportunities for integrated programs, enabling clients to consolidate outsourced activities under oneCRDMO partner.

Investments & Assets Recent equity investments and asset acquisitions in Western Europe indicate a strategic push into new geographies and capabilities, suggesting sales potential in Europe-focused programs and in-sourcing of specialized technologies.

Scale & Quality A substantial workforce and multi-regional operations emphasize capacity and quality assurances, making Jubilant Biosys a compelling option for large, multi-country drug development programs requiring robust project delivery and regulatory readiness.